← Back to Search

Janus Kinase (JAK) Inhibitor

Upadacitinib for Vitiligo

Phase 2
Waitlist Available
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 24 weeks
Awards & highlights

Study Summary

This trial will evaluate the safety and efficacy of upadacitinib in participants with non-segmental vitiligo.

Eligible Conditions
  • Vitiligo

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent Change From Baseline in Facial-Vitiligo Area Scoring Index (F-VASI)
Secondary outcome measures
Change From Baseline in the Vitiligo Quality-of-Life (VitiQoL) Instrument Total Score
Percent Change From Baseline in T-VASI
Percentage of Participants Achieving F-VASI 50 (≥ 50% Improvement in F-VASI From Baseline)
+2 more

Side effects data

From 2023 Phase 3 trial • 613 Patients • NCT03086343
6%
URINARY TRACT INFECTION
5%
UPPER RESPIRATORY TRACT INFECTION
5%
NASOPHARYNGITIS
3%
HYPERTENSION
100%
80%
60%
40%
20%
0%
Study treatment Arm
Abatacept
Upadacitinib 15 mg

Trial Design

5Treatment groups
Experimental Treatment
Group I: Placebo Followed by Dose B of UpadacitinibExperimental Treatment2 Interventions
Participants in this group will receive placebo for 24 weeks followed by dose B of upadacitinib orally QD for 28 weeks.
Group II: Placebo Followed by Dose A of UpadacitinibExperimental Treatment2 Interventions
Participants in this group will receive placebo for 24 weeks followed by dose A of upadacitinib orally QD for 28 weeks.
Group III: Dose C of UpadacitinibExperimental Treatment1 Intervention
Participants in this group will receive dose C of upadacitinib orally QD for 52 weeks.
Group IV: Dose B of UpadacitinibExperimental Treatment1 Intervention
Participants in this group will receive dose B of upadacitinib orally QD for 52 weeks.
Group V: Dose A of UpadacitinibExperimental Treatment1 Intervention
Participants in this group will receive dose A of upadacitinib orally once daily (QD) for 52 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Upadacitinib
2014
Completed Phase 3
~9670
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

AbbVieLead Sponsor
954 Previous Clinical Trials
500,920 Total Patients Enrolled
1 Trials studying Vitiligo
540 Patients Enrolled for Vitiligo
ABBVIE INC.Study DirectorAbbVie
394 Previous Clinical Trials
145,754 Total Patients Enrolled
1 Trials studying Vitiligo
540 Patients Enrolled for Vitiligo

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the eligibility for this experiment extend to those aged 80 and above?

"According to the trial's requirements for participation, applicants must be 18 or older and no more than 65 years old."

Answered by AI

Have there been any other clinical tests utilizing Upadacitinib?

"Upadacitinib was initially studied at AZ Arthritis and Rheum Assoc /ID# 143130 in 2015, with a total of 18329 trials concluding since then. At the moment, 21 active clinical studies are underway; many located in Irvine, California."

Answered by AI

Is this an unprecedented clinical trial?

"Upadacitinib has been a subject of clinical research since 2015, when AbbVie first sponsored the drug's initial trial comprising 1629 patients. After its Phase 3 approval in that same year, 21 active trials have now opened up across 54 countries and 953 cities."

Answered by AI

What risks have been associated with using Upadacitinib for treatment?

"Due to the data available from Phase 2 trials, our team at Power considers upadacitinib's safety rating as a 2 on a scale of 1-3. As this is an early trial stage, there has yet to be evidence supporting its efficacy."

Answered by AI

Are there any opportunities remaining to participate in this investigation?

"According to the clinicaltrials.gov database, this medical study is not presently seeking participants - even though it was originally posted on June 16th 2021 and last updated August 3rd 2022. Fortunately, 58 other trials are now open for enrolment."

Answered by AI

What is the target enrollment for this clinical experiment?

"This trial has ceased recruiting, having last been updated on August 3rd 2022. If you are looking for other clinical trials related to vitiligo or Upadacitinib there are 37 and 21 studies respectively that require patients."

Answered by AI

What prerequisites must be fulfilled to participate in this investigation?

"This medical study is seeking 185 people with vitiligo that are of legal age and not older than 65."

Answered by AI

What medical conditions are most commonly treated with Upadacitinib?

"Upadacitinib is routinely prescribed to patients in need of systemic therapy, particularly those with rheumatoid arthritis, methotrexate resistance, and unsatisfactory outcomes from traditional treatments."

Answered by AI

Who else is applying?

What state do they live in?
Tennessee
Ontario
Massachusetts
Other
How old are they?
18 - 65
What site did they apply to?
Research Toronto /ID# 228401
University of California Irvine /ID# 229390
UMass Memorial Medical Center /ID# 228066
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
2
0

Why did patients apply to this trial?

Tried serval creams/ointments in the past. Ive never tried anything to treat my vitiligo.
PatientReceived no prior treatments
I have vitiligo and I have been following the recent developments in the management of Vitiligo.
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
2021. "Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04927975.
~48 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top